MA41962A - Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t - Google Patents
Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules tInfo
- Publication number
- MA41962A MA41962A MA041962A MA41962A MA41962A MA 41962 A MA41962 A MA 41962A MA 041962 A MA041962 A MA 041962A MA 41962 A MA41962 A MA 41962A MA 41962 A MA41962 A MA 41962A
- Authority
- MA
- Morocco
- Prior art keywords
- chemerical
- adoptive
- cell therapy
- receptor targeting
- antigenic receptor
- Prior art date
Links
- 230000000890 antigenic effect Effects 0.000 title 1
- 238000002659 cell therapy Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/17—Hinge-spacer domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562151609P | 2015-04-23 | 2015-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41962A true MA41962A (fr) | 2018-02-28 |
Family
ID=57144257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041962A MA41962A (fr) | 2015-04-23 | 2016-04-22 | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t |
Country Status (4)
Country | Link |
---|---|
US (2) | US10786549B2 (fr) |
EP (1) | EP3286225B1 (fr) |
MA (1) | MA41962A (fr) |
WO (1) | WO2016172606A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017005106A (es) | 2014-10-20 | 2017-07-05 | Juno Therapeutics Inc | Metodos y composiciones para dosificacion en terapia celular adoptiva. |
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
SG11201706774WA (en) * | 2015-02-27 | 2017-09-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
WO2016172606A1 (fr) * | 2015-04-23 | 2016-10-27 | Baylor College Of Medicine | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t |
GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
GB201622044D0 (en) * | 2016-12-22 | 2017-02-08 | Ucl Business Plc | T cell-targeted T cells |
KR20190142775A (ko) | 2017-04-19 | 2019-12-27 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 조작된 항원 수용체를 발현하는 면역 세포 |
AU2018275894A1 (en) * | 2017-06-02 | 2019-12-12 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
EP3638261A4 (fr) * | 2017-06-12 | 2021-03-10 | Emory University | Récepteur d'antigène chimérique (car) ciblant l'antigène de lymphocyte t et utilisations dans des thérapies cellulaires |
WO2019143961A2 (fr) * | 2018-01-19 | 2019-07-25 | The Trustees Of The University Of Pennsylvania | Compositions et méthodes de ciblage de lymphocytes t gamma delta au moyen de récepteurs antigéniques chimériques |
EP3781592A4 (fr) * | 2018-04-20 | 2023-01-11 | The Regents of the University of California | Traitement du cancer de la prostate au moyen de récepteurs antigéniques chimériques |
WO2020097193A1 (fr) | 2018-11-06 | 2020-05-14 | The Regents Of The University Of California | Récepteurs antigéniques chimériques pour la phagocytose |
CA3137373A1 (fr) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Conjugues anticorps-medicaments d'amatoxine et leurs utilisations |
US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
BR112021021843A8 (pt) * | 2019-04-30 | 2022-06-21 | Myeloid Therapeutics Inc | Composições de proteínas de fusão quiméricas modificadas e método de uso das mesmas |
CA3138991A1 (fr) * | 2019-05-02 | 2020-11-05 | Ligandal, Inc. | Methodes et compositions pour l'administration d'agents therapeutiques ciblee sur des ligands, sensible au diagnostic |
GB2605276A (en) | 2019-09-03 | 2022-09-28 | Myeloid Therapeutics Inc | Methods and compositions for genomic integration |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
US20240002505A1 (en) * | 2020-11-01 | 2024-01-04 | Nanjing IASO Biotechnology Co., Ltd. | Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof |
JP2023549140A (ja) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス,インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびその使用方法 |
WO2022115864A1 (fr) * | 2020-11-30 | 2022-06-02 | Simcere Innovation, Inc. | Cellules immunitaires universelles exprimant un récepteur antigénique chimérique pour une thérapie cellulaire allogénique |
EP4279508A1 (fr) * | 2021-01-12 | 2023-11-22 | Nanjing Iaso Biotechnology Co., Ltd. | Anticorps entièrement humanisé ciblant cd5 |
JP2024505600A (ja) | 2021-02-03 | 2024-02-06 | モーツァルト セラピューティクス, インコーポレイテッド | 結合剤およびそれを使用する方法 |
KR20220148745A (ko) * | 2021-04-29 | 2022-11-07 | 한국생명공학연구원 | 신규한 항-cd5 키메릭 항원 수용체 및 이를 발현하는 면역세포 |
WO2023076876A1 (fr) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation de réponses immunitaires à des vecteurs viraux |
WO2023086900A1 (fr) * | 2021-11-10 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Cellules microgliales de récepteur antigénique chimérique (car) génétiquement modifiées pour le traitement de troubles neurodégénératifs |
WO2023198744A1 (fr) * | 2022-04-13 | 2023-10-19 | Tessa Therapeutics Ltd. | Produit de lymphocytes t thérapeutiques |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US20110250203A1 (en) | 2008-08-29 | 2011-10-13 | Symphogen A/S | Anti-cd5 antibodies |
AU2013221672B2 (en) * | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
KR102198058B1 (ko) * | 2012-10-02 | 2021-01-06 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
EP3858378A1 (fr) * | 2013-11-21 | 2021-08-04 | Autolus Limited | Cellule |
SG11201706774WA (en) | 2015-02-27 | 2017-09-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
WO2016172606A1 (fr) * | 2015-04-23 | 2016-10-27 | Baylor College Of Medicine | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t |
US20180371052A1 (en) * | 2015-12-22 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
-
2016
- 2016-04-22 WO PCT/US2016/029014 patent/WO2016172606A1/fr unknown
- 2016-04-22 MA MA041962A patent/MA41962A/fr unknown
- 2016-04-22 US US15/568,702 patent/US10786549B2/en active Active
- 2016-04-22 EP EP16784012.3A patent/EP3286225B1/fr active Active
-
2020
- 2020-08-24 US US17/000,617 patent/US20200405811A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2016172606A1 (fr) | 2016-10-27 |
US20180104308A1 (en) | 2018-04-19 |
EP3286225B1 (fr) | 2020-07-01 |
US10786549B2 (en) | 2020-09-29 |
EP3286225A1 (fr) | 2018-02-28 |
US20200405811A1 (en) | 2020-12-31 |
EP3286225A4 (fr) | 2018-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41962A (fr) | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t | |
DK3440105T3 (da) | T-cellereceptorer | |
DK3440106T3 (da) | T-cellereceptorer | |
MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
HK1253695A1 (zh) | T細胞受體特異性抗體 | |
BR112017012502A2 (pt) | receptor quimérico de antígeno bcma | |
DK3394094T3 (da) | T-celle receptorer specifikke for ny-eso-1 tumor antigen-hla-a*02 komplekset | |
BR112017005630A2 (pt) | células t de memória central para terapia adotiva com células t | |
DK3494133T3 (da) | Anti-kras-g12d-t-cellereceptorer | |
DK3514172T3 (da) | Claudin-6-specifikke immunoreceptorer og t-celleepitoper | |
IL263513A (en) | Enhanced activated t-cell therapy (act). | |
MA55694A (fr) | Méthodes de conditionnement de patients pour la thérapie cellulaire t | |
DK3368060T3 (da) | Glugacon-receptor-agonister | |
DK3283110T3 (da) | Antistoffer rettet mod interleukin-36-receptor (il-36r) | |
DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
DK3151672T3 (da) | Forbedrede t-celle-sammensætninger | |
DK3129063T3 (da) | Anti-her3-antistof-lægemiddelkonjugat | |
DK3359160T3 (da) | Farnesoid x receptor modulatorer | |
DK3433280T3 (da) | Protease-aktiverede T-celle-bispecifikke molekyler | |
IL274025A (en) | A new T-cell receptor | |
DK3268067T3 (da) | Lægemiddeladministrationsanordning | |
DK3191182T3 (da) | Apparat til tilvejebringelse af hypertermiterapi | |
GB2556969B (en) | Multi-functional electro-spoon needle therapeutic apparatus | |
DK3529262T3 (da) | Fremgangsmåder til fremme af t-cellerespons | |
DK3490986T3 (da) | Piperidin-cxcr7-receptormodulatorer |